Skip to main content

jeuveau

Generic: PRABOTULINUMTOXINA-XVFS

jeuveau: sourced relationships with 1 company · 1 FDA decision.

jeuveau evidence translation

What we can confirm

What it means

Source-backed records connect jeuveau to EOLS; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could jeuveau → EOLS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

temporary improvement in the appearance of moderate to severe glabellar lines

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Evolus, Inc. (EOLS)
developer · Reported 2024-03-07 · Current development: unknownSource
temporary improvement in the appearance of moderate to sever…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ( 1 )(EOLS)FDA ↗
BLA761085Type 1 - New Molecular EntityStandardOtherInjectable

Frequently asked questions

Which companies have sourced relationships with jeuveau?

jeuveau has dated SEC/FDA relationship records for Evolus, Inc..

What is jeuveau's latest FDA decision?

The most recent tracked FDA decision for jeuveau is Approval for 1 INDICATIONS AND USAGE JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ( 1 ), dated February 1, 2019.